Healthcare Triangle closes $6.5 million private placement
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
An algorithm based testing for Fatty Liver Disease
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Company is investing more than €100 million in the expansion of the Halle site
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Subscribe To Our Newsletter & Stay Updated